Abbott Laboratories
ABT · NYSE
Analyst Consensus
Analyst Ratings Synthesis
The supplied consensus is Buy across 20 analysts, with price targets clustered between $118 and $125, a $7 spread, and a mean of $120. The named actions show a more cautious tone: Argus downgraded Abbott from Buy to Hold, while RBC lowered its target from $130 to $125 but retained an Outperform rating. RBC’s $125 target is the highest target explicitly attributed to a named firm in the evidence; Argus is the most cautious named rating. The evidence does not establish a comprehensive week-only revision trend: RBC’s change is dated October 22, and the Argus snippet gives no action date. The substantive disagreement is whether the diversified healthcare portfolio can offset the near-term sales-growth guidance cut and nutrition weakness.
- Tarsus Names Neera Clase Commercial Chief To Expand XDEMVY Reach And Lead Pipeline Planning
- SCHD, COP, CVX, ABT: ETF Inflow Alert
- Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
- Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now?
- This Dividend King Just Announced Great News for Investors
Rating Actions
| Firm | Analyst | Rating | Price Target | Upside | Date | Source |
|---|---|---|---|---|---|---|
| BTIG Research | — | $125 | +14.3% | Oct 22, 2026 | Open the report this row came from | |
| Royal Bank of Canada | — | $125 | +14.3% | Oct 22, 2026 | Open the report this row came from | |
| JPMorgan | — | $118 | +7.9% | Oct 16, 2026 | Open the report this row came from | |
| RBC Capital | — | $125 | +14.3% | Oct 16, 2026 | Open the report this row came from | |
| Citigroup | Joanne Wuensch | $122 | +11.5% | Oct 16, 2026 | Open the report this row came from | |
| Rothschild & Co | — | — | — | Oct 2, 2026 | Open the report this row came from | |
| Freedom Broker | — | $120 | +9.7% | Jan 29, 2026 | Open the report this row came from | |
| UBS | — | $125 | +14.3% | Oct 17, 2023 | Open the report this row came from |
Research Reports
- Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
- Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now?
- This Dividend King Just Announced Great News for Investors
- Abbott Laboratories vs. UnitedHealth: Does Health Innovation or Health Insurance Make for a Better Stock to Buy?
- Abbott Labs (ABT) Stock Forecast: Analyst Ratings, Predictions & Price Target 2026
- What is the current Price Target and Forecast for Abbott Laboratories (ABT)
- Abbott Laboratories (ABT) Stock Forecast and Price Target 2026 $ABT
- Argus downgrades Abbott Labs stock rating on guidance cut
- Abbott Laboratories (ABT) Stock Forecast, Price Targets and Analysts Predictions
- Argus Downgrades Abbott Laboratories to Hold From Buy
- Recent Investment Analysts’ Ratings Updates for Abbott Laboratories (ABT)
